RxDoctor Payments Data

Amy Perez, NP

Adult Health · Atlanta, GANPI 1235597808

Payments from drug & device makers

$1,160in general payments, 2019–2025

Across 24 payments — averaging $48.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$357
  • Cvrx, Inc.$189
  • Abbott$168
  • Genentech USA, Inc.$123
  • Axsome Therapeutics, Inc.$122
  • E.r. Squibb & Sons, L.L.C.$75
  • plus $125 from 5 others

What the payments were for

  • Food & beverage$1,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,160 in reported general payments places this provider in the 65th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia

Medicare billing

Part B allowed, 2024
$11,478
Medicare patients
80
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe185$159,476
UbrelvyUbrogepant50$49,753
Nurtec OdtRimegepant Sulfate38$35,439
Emgality SyringeGalcanezumab-Gnlm16$34,706
Emgality PenGalcanezumab-Gnlm24$23,098
Tetrabenazine11$17,773
Levetiracetam290$17,287
QuliptaAtogepant12$13,219
Lacosamide128$7,280
Acetazolamide ErAcetazolamide16$2,078
Divalproex Sodium53$1,886
Sumatriptan Succinate95$1,805
Carbamazepine ErCarbamazepine17$1,748
Carbamazepine11$1,413
Oxcarbazepine22$1,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$357$62,97262 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$17$87617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 577 adult health providers in Georgia.

Other adult health in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →